BACKGROUND: The hepatic outcome of hepatitis B surface antigen (HBsAg) positive patients undergoing chemotherapy after withdrawal of pre-emptive lamivudine is unknown. AIMS: To examine the occurrence of hepatitis B virus (HBV) reactivation after withdrawal of pre-emptive lamivudine. METHODS: Pre-emptive lamivudine was started one week before initiation of chemotherapy in 46 consecutive HBsAg positive patients and continued for the entire duration of chemotherapy. Pre-emptive lamivudine was stopped at a median 3.1 (range 3.0-3.4) months after completion of chemotherapy. Patients were longitudinally followed up after withdrawal of pre-emptive lamivudine. RESULTS: Median time of follow up after withdrawal of lamivudine was 25.7 (range 5.7-75.7) months. Eleven of the 46 patients (23.9%) developed HBV reactivation after withdrawal of pre-emptive lamivudine. Eight of the 16 patients with high pre-chemotherapy HBV DNA (> or =10(4) copies/ml) compared with three of the 30 patients with low pre-chemotherapy HBV DNA (<10(4) copies/ml) developed HBV reactivation (50.0% v 10.0%, respectively; p<0.001). Hepatitis B e antigen positive patients were also more likely to develop HBV reactivation (5/11 (45.5%) v 6/35 (17.1%), respectively; p = 0.041). A high pre-chemotherapy HBV DNA (> or =10(4) copies/ml) was the most important risk factor for HBV reactivation after withdrawal of pre-emptive lamivudine on Cox proportional hazards analysis (relative risk 16.13, (95% confidence interval 2.99-87.01; p = 0.001). CONCLUSIONS: HBV reactivation is more likely to occur in patients with high pre-chemotherapy HBV DNA after withdrawal of pre-emptive lamivudine. A more prolonged course of antiviral therapy may be necessary in these patients after completion of chemotherapy in order to reduce post-chemotherapy HBV reactivation.
BACKGROUND: The hepatic outcome of hepatitis B surface antigen (HBsAg) positive patients undergoing chemotherapy after withdrawal of pre-emptive lamivudine is unknown. AIMS: To examine the occurrence of hepatitis B virus (HBV) reactivation after withdrawal of pre-emptive lamivudine. METHODS: Pre-emptive lamivudine was started one week before initiation of chemotherapy in 46 consecutive HBsAg positive patients and continued for the entire duration of chemotherapy. Pre-emptive lamivudine was stopped at a median 3.1 (range 3.0-3.4) months after completion of chemotherapy. Patients were longitudinally followed up after withdrawal of pre-emptive lamivudine. RESULTS: Median time of follow up after withdrawal of lamivudine was 25.7 (range 5.7-75.7) months. Eleven of the 46 patients (23.9%) developed HBV reactivation after withdrawal of pre-emptive lamivudine. Eight of the 16 patients with high pre-chemotherapy HBV DNA (> or =10(4) copies/ml) compared with three of the 30 patients with low pre-chemotherapy HBV DNA (<10(4) copies/ml) developed HBV reactivation (50.0% v 10.0%, respectively; p<0.001). Hepatitis B e antigen positive patients were also more likely to develop HBV reactivation (5/11 (45.5%) v 6/35 (17.1%), respectively; p = 0.041). A high pre-chemotherapy HBV DNA (> or =10(4) copies/ml) was the most important risk factor for HBV reactivation after withdrawal of pre-emptive lamivudine on Cox proportional hazards analysis (relative risk 16.13, (95% confidence interval 2.99-87.01; p = 0.001). CONCLUSIONS:HBV reactivation is more likely to occur in patients with high pre-chemotherapy HBV DNA after withdrawal of pre-emptive lamivudine. A more prolonged course of antiviral therapy may be necessary in these patients after completion of chemotherapy in order to reduce post-chemotherapy HBV reactivation.
Authors: Yun-Fan Liaw; Nancy Leung; Richard Guan; George K K Lau; Ismail Merican; Geoff McCaughan; Edward Gane; Jia-Horng Kao; Masao Omata Journal: Liver Int Date: 2005-06 Impact factor: 5.828
Authors: M G Peters; G Singer; T Howard; S Jacobsmeyer; X Xiong; C S Gibbs; P Lamy; A Murray Journal: Transplantation Date: 1999-12-27 Impact factor: 4.939
Authors: Chee-kin Hui; Jian Sun; Wing-yan Au; Albert K W Lie; Yui-hung Yueng; Hai-ying Zhang; Nikki P Lee; Jin-ling Hou; Raymond Liang; George K K Lau Journal: J Hepatol Date: 2005-03-31 Impact factor: 25.083
Authors: F Silvestri; A Ermacora; A Sperotto; F Patriarca; F Zaja; D Damiani; R Fanin; M Baccarani Journal: Br J Haematol Date: 2000-02 Impact factor: 6.998
Authors: D Mutimer; D Pillay; P Shields; P Cane; D Ratcliffe; B Martin; S Buchan; L Boxall; K O'Donnell; J Shaw; S Hübscher; E Elias Journal: Gut Date: 2000-01 Impact factor: 23.059
Authors: Chee-Kin Hui; Scott Bowden; Kathy Jackson; Wing-yan Au; Daniel Y T Fong; Albert K W Lie; Chor-sang Chim; Raymond Liang; George K K Lau Journal: Blood Date: 2005-03-15 Impact factor: 22.113
Authors: C L Lai; R N Chien; N W Leung; T T Chang; R Guan; D I Tai; K Y Ng; P C Wu; J C Dent; J Barber; S L Stephenson; D F Gray Journal: N Engl J Med Date: 1998-07-09 Impact factor: 91.245
Authors: Chee-Kin Hui; Scott Bowden; Hai-Ying Zhang; Anita Wong; Sharon Lewin; Frank Rousseau; Herve Mommeja-Marin; Nikki P Lee; John M Luk; Stephen Locarnini; Nancy Leung; Nikolai V Naoumov; George K K Lau Journal: J Clin Microbiol Date: 2006-08 Impact factor: 5.948
Authors: Man Fai Law; Rita Ho; Carmen K M Cheung; Lydia H P Tam; Karen Ma; Kent C Y So; Bonaventure Ip; Jacqueline So; Jennifer Lai; Joyce Ng; Tommy H C Tam Journal: World J Gastroenterol Date: 2016-07-28 Impact factor: 5.742